|

The Role of hs Troponin I and NT-proBNP in Predicting Atrial Fibrillation in Patients With Permanent Pacemakers

RECRUITINGSponsored by University of Medicine and Pharmacy at Ho Chi Minh City
Actively Recruiting
SponsorUniversity of Medicine and Pharmacy at Ho Chi Minh City
Started2023-12-01
Est. completion2026-09-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06174506

Summary

The goal of this clinical trial is to answer the research question whether hs Troponin I and NT-proBNP have a role in detecting atrial fibrillation in patients with pacemakers. Objectives of the study: 1. To survey some risk factors for atrial fibrillation in patients with permanent pacemakers. 2. To determine the role of hs Troponin I and NT-proBNP in predicting new-onset atrial fibrillation within follow-up time. 3. To build a model to predict the prognosis of atrial fibrillation based on the detected subclinical markers related to atrial fibrillation and classic cardiovascular risk factors.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patient is an adult (≥ 18 years old or older)
* There is indication for permanent pacemaker placement and patient agreement to permanent pacemaker placement
* Patient agrees to participate in the study

Exclusion Criteria:

* Patients had a diagnosis of atrial fibrillation in their past history or atrial fibrillation is discovered at the time of participating in the study
* Severe patients, at risk of death
* Pregnant
* The patient is indicated for surgery
* Patients with eGFR ≤ 30 mL/min/1.73m2
* The patient has a serious infection

Conditions2

Atrial FibrillationHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.